showing an impairment of anti-CD20 antibody binding. However, further clinical studies suggested an improved outcome associated with their use in hematological malignancies. In particular, a survival benefit was reported for patients with follicular lymphoma on statins.
INTRODUCTION
Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma (NHL). Most patients have disseminated disease at presentation, but immediate treatment with immunotherapy or immunochemotherapy is not always required since the disease usually follows an indolent course. 1 When treatment is initiated, FL is characterized by a high initial response rate but in most patients the disease will ultimately relapse, although recent data suggest that prolonged PFS can be achieved with first line treatment. 2, 3 However, subsequent remissions are usually of sequentially shorter durations. 4 After decades of disappointing results, overall survival has recently improved since the addition of rituximab to the therapeutic armamentarium in FL. [5] [6] [7] [8] [9] [10] [11] However, no cure of the disease is suggested in recent trials or long-term follow-up studies of conventional chemotherapy despite the broad use of anti-CD20 containing regimen. 12, 13 New treatment strategies are therefore needed to improve the prognosis of patients with FL, especially those exhibiting adverse prognostic characteristics at diagnosis. To this end, new monoclonal antibodies and/or combined targeted therapies are currently in development or evaluated within clinical trials with promising results. 14, 15 Little is known about the possible beneficial effect of concomitant non-antineoplastic medication when immunochemotherapy is utilized. In this regard, conflicting results have been published to date concerning the impact of statin use on the prognosis of patients with NHL treated with a rituximab-containing first-line regimen. Accumulating evidence suggests that statin use has a potential antitumor effect 16 in addition to their known ability to improve dyslipidemia and reduce cardiovascular morbidity and mortality. 17 Recent studies suggest reduced cancer-specific mortality after prostate cancer diagnosis among statin users. 16, 18 Paradoxically, an adverse prognostic impact of statin use in lymphoma was suspected from in vitro data showing an impairment of anti-CD20 antibody binding due to changes in 5 conformational epitopes of the molecule by an outer plasma membrane cholesterol-dependent mechanism. As a result, statins were found to decrease anti-CD20 induced complementdependent cytotoxicity and antibody-dependent cellular cytotoxicity. 19, 20 Several groups worldwide attempted to assess the outcome of patients concomitantly receiving statins and rituximab for NHL. No detrimental effect was observed across studies for patients with diffuse large B-cell lymphoma treated upfront with R-CHOP or R-CHOPlike regimens 21, 22 or for patients with chronic lymphoid leukemia (CLL) either during "watchful waiting" or treatment with a rituximab-containing therapy. 23 However, an unexpected prolongation of event-free survival (EFS) was observed for patients with FL receiving statins in a study from Nowakowski et al. 21 Several caveats of the study precluded definitive conclusions to be drawn; including treatment heterogeneity, the enrollment of patients who did not receive rituximab, the retrospective assessment of statin use through medical charts and the consideration of EFS as the primary endpoint without specific evaluation of overall survival (OS). 21 Notably, another recent study demonstrated a favorable outcome for patients with relapsed/refractory CLL both on statins and aspirin and treated by a rituximab-fludarabine-cyclophosphamide (FCR) regimen. 23 The impact of statin use on the prognosis of patients with FL therefore requires further investigation.
The PRIMA study is an international open-label phase III trial in which 1217 patients with de novo FL were enrolled. The trial demonstrated a favorable outcome in terms of EFS for patients receiving a 2-year maintenance treatment with rituximab on a bi-monthly basis following an induction immunochemotherapy regimen. 24 Since all concomitant medications were registered at enrollment, the study provided the opportunity to specifically analyze the effect of statin use during initial treatment on outcome.
Our objective is to determine whether the outcome of follicular lymphoma patients treated in the PRIMA study with immunochemotherapy was favorably effected by the antineoplastic 6 action of statins or detrimentally effected by the potential adverse action of statins on anti CD20 binding.
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PATIENTS AND METHODS
Study Population
The randomized, open-label PRIMA study enrolled 1217 patients with de novo FL from 223 centers in 25 countries. Patients achieving at least a partial response following frontline therapy with physician-selected R-CHOP, R-CVP or R-FCM were randomized between 2-years rituximab maintenance (every 8 weeks) or observation.
24
Patients with grade 1, 2, or 3a FL were eligible for induction if they were older than 18 years and presented with at least one high burden criterion among the following: any nodal or extranodal tumor mass with a diameter greater than 7 cm, involvement of three nodal sites with a diameter greater than 3 cm, systemic symptoms, substantial splenic enlargement, any compression syndrome (ureteral, orbital, gastrointestinal) , or serous effusion (irrespective of cell content), elevated serum levels of lactic dehydrogenase (LDH) or ß 2 -microglobulin (above upper normal limit).
Patients with responding disease (either complete or partial) were randomly assigned in a 1:1 ratio to receive 2 years of rituximab maintenance therapy (375mg/m 2 IV every 8 weeks) or observation (see flowchart in supplementary figure 1 ) but all enrolled patients before the induction phase were considered in the present study.
The PRIMA study was registered on the National Institute of Health website, number NCT00140582.
The protocol was approved by local or national ethics committees according to the laws of each country and the study was in accordance with the declaration of Helsinki. All patients gave written informed consent before registration.
The trial demonstrated a significant improvement of the primary endpoint (i.e. progressionfree survival (PFS) from randomization) in the rituximab maintenance arm. 24 3-year PFS was 8 74.9% (95% CI 70.9-78.9) in the rituximab maintenance group and 57.6% (95% CI 53.2-62.0) in the observation group (stratified log rank, P<.0001).
Statin Exposure
All concomitant treatments at study enrollment, including the use of statins, were prospectively collected. Concomitant treatments at therapy initiation were registered only if continuing at least up to 4 weeks during the trial.
Statistical analysis
Statistical analyses were performed using SAS version 9.2 for PC (SAS Institute, Cary, NC).
A P value <.05 was considered as statistically significant. All statistical tests were 2-sided.
Baseline demographic characteristics between patients on statins and those not on statins were compared with the use of a Chi-square test. In the original PRIMA study publication, 24 all time-to-event evaluations were calculated from the date of randomization to the date of the event considered. Since effect of statins use during induction therapy was of interest in the present study, all time-to-event endpoints presented here were calculated from the date of the first induction course with R-CHOP, R-CVP or R-FCM. EFS, time-to-next lymphoma treatment (TTNLT) and time-to-next chemotherapy (TTNCT) were defined according to IWG 1999. 25 Specifically, EFS was defined as the interval between the date of induction to the date of first documented disease progression, relapse, initiation of a new anti-lymphoma treatment or death from any cause. EFS was used as an endpoint instead of PFS so that results could be compared to previously published data concerning the prognostic impact of statins in patients with FL. 21 Patients with ongoing responding disease and patients who were lost to follow-up were censored at their last tumor assessment date.
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All endpoints were examined in univariate and multivariate analyses. Three different multivariate hazard ratio Cox regression models were used to assess the prognostic value of statin use after adjustment for potentially confounding factors.
A first model included imbalanced prognostic variables between statin patients and non-statin patients with a level of significance set up at 0.1 (as listed in Table 1 Table 1 ). Given a proportion of patients did not achieve at least PR to induction and therefore were not randomized to the maintenance/observation phase, maintenance as such could not be included as a variable in the models. Level for entry into the model was set at 0.2 with a stay level of 0.05. Importantly, statin use was forced into the model since it was the variable of interest in the study.
RESULTS
Patient Characteristics at Baseline
Among the 1217 patients enrolled in the PRIMA study, 1135 were included in the present study. Fifteen were excluded because of premature sites closure, 58 because of other lymphoma subtype diagnosis at central histological review and 9 because of consent withdrawal before any treatment (Supplementary Figure S1) . Concomitant treatments at registration were available for all patients. Among those 1135 patients, 119 were on statins (10.5%) at diagnosis. Patient characteristics according to statin use are presented in Table 1 .
Details on statin subtypes for the study population are provided in Supplementary Table S1 and a flowchart according to statin use is presented in Supplementary Figure S1 .
The use of any statin was associated with an older age at registration and, partly as a consequence, to a higher FLIPI risk score. Median age for the cohort was 57 years (range, 22-87). Overall 50 of 733 (6.8%) of those age ≤60 used statins, whereas 69 of 402 (17.2%) of those age >60 (P<.001). In the high FLIPI risk category, 14% of patients were on statins compared to 5% in the low risk category (P<.001). Male sex and disseminated disease was also overrepresented among statin users, although not significantly (P=.076 and P=.074 respectively). LDH was more frequently above the upper normal limit (P=.03). No other differences were observed with regards to demographic data, induction treatment or maintenance allocation according to statin use (Table 1 and Supplementary Table S2 ).
Treatment Toxicities According to Statin Use
The rate of adverse events (AE) between the 2 groups of patients was comparable, in terms of both the incidence of AE of any grade or of grade 3/4. This was observed when analyzing the entire treatment schedule (induction and maintenance) or just the induction phase using R- Table S5 ).
CHOP or R-CVP regimens (Supplementary
Disease Response Rate According to Statin Use
No differences in overall response rate to induction regimen, nor in the quality of the response (CR/CRu versus PR versus others) was noted (P=.52) ( Table 2) . No further differences were found at the end of the maintenance period (P=.67). Subgroup analyses by maintenance arm displayed similar response rates either for patients in the observation arm compared to the rituximab treatment arm (data not shown).
Survival According to Statin Use
Outcome in terms of EFS, TTNLT, TTNCT and OS were similar regardless of the use of statins (P=.57, P=.85, P=.30 and P=.43 respectively) in univariate analysis (Fig 1A-D) . In patients treated on the PRIMA study there was no significant effect of statins on response rate or survival, even after adjustment for potential confounding factors (especially age and gender), was observed. 10.5% of patients were on statins at enrollment consistent with the estimated one in ten adults in the general population among US adults. 29 Importantly, all patients on this prospective randomized trial presented with stage II, III or IV disease with at least one high tumor burden criterion and required immediate treatment for FL. They were homogeneously treated with a rituximab-containing immuno-chemotherapy regimen at induction (mainly R-CHOP or R-CVP therapy) and, in case of response, were further randomized between observation and rituximab maintenance for 2 years. Those results are in accordance with findings by Ennishi et al. in diffuse large B-cell lymphoma where no 13 detrimental effect was observed among patients on statins. 30 They also confirm that no treatment interruption is required for statins at lymphoma diagnosis in FL subtype.
In 2009, a report from the Mayo Clinic, Rochester, described a benefit of statin therapy on FL outcome, as assessed by EFS based on a registry data and prospective observation (N=289).
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Notably, 35% of patients in the present cohort were older than 60 years compared to 54% in the FL subpopulation of the aforementioned study. As a result, at least in part, 21% of patients were on statins compared to 10% in our study. Furthermore, patients had undergone heterogeneous treatments; 40% of patients with FL were in a "watch and wait" approach, and only 41% received a rituximab-containing therapy. Although all patients in this study seem to benefit from statin use, a more significant impact was observed among patients on observation. Hence, the prolonged EFS observed with statin use was consistent across patients treated with rituximab-based regimen or whose initial therapy was observation only but within a thinner range of confidence interval for the later (95% CI 0.14-1.07 versus 0.17- 
